Multiple Sclerosis, Relapsing-remitting Clinical Trial
Official title:
Randomized Control Trial Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple Sclerosis: A Pilot Study
NCT number | NCT02687919 |
Other study ID # | 201208703 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | October 2012 |
Est. completion date | October 2014 |
Verified date | July 2019 |
Source | University of Iowa |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a research study. The investigators are inviting participants to participate in this
research study between the ages of 18-45, who have stable Relapsing-Remitting Multiple
Sclerosis (RRMS), are able to walk 25 ft with/without an assistive device, and have none of
the following: liver disease, kidney disease, diabetes, active heart disease, heart block or
arrhythmias, bleeding disorders, concurrent diuretic use, anti-coagulation or anti-platelet
use, psychosis or other psychiatric disorder likely to impact ability to comply with study
procedures, any change in prescription medication for a mental health problem such as
depression or anxiety in the last three months.
The purpose of this research study is to determine whether or not a modified Paleolithic diet
results in any change in health in persons with RRMS compared to usual care. The
investigators define usual care as the typical or usual physician recommendations for the
treatment of RRMS.
The Paleolithic diet (or Paleo diet), also referred to as the caveman diet, Stone Age diet,
and hunter-gatherer diet, is a modern nutritional plan based on the presumed ancient diet of
wild plants and animals of ancestral humans during the Paleolithic era (a period of about 2.5
million years duration that ended around 10,000 years ago with the development of
agriculture). The diet consists mainly of fish, grass-fed pasture raised meats, vegetables,
fruit, fungi, roots, and nuts, and excludes grains, legumes, dairy products, salt, refined
sugar, and processed oils.
To the investigators' knowledge, most neurologists prescribe medications that may reduce or
prevent future disability, but few prescribe dietary modifications unless needed for other
concomitant disease.
Status | Completed |
Enrollment | 31 |
Est. completion date | October 2014 |
Est. primary completion date | September 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: 1. Verified diagnosis of relapsing-remitting multiple sclerosis (RRMS) with no change in medications in the prior three months. 2. Able to ambulate a minimum of 25 feet with/without use of an assistive device. Exclusion Criteria: 1. Under the age of 18 or over the age of 45 at the beginning of the study. 2. Unstable MS, requiring a change in medication in the prior 3 months. 3. Unwillingness to contact, or allow research to contact, neurologist for verification of RRMS diagnosis. 4. Psychosis or other psychiatric disorder likely to impact ability to comply with study procedures. 5. Change in prescriptions medication in the prior three months for a mental health problem such as depression or anxiety. 6. Active malignancy undergoing treatment (not including non melanoma skin cancers). 7. Subjects with liver disease, kidney disease, diabetes, active heart disease, heart block or arrhythmias, bleeding disorders, concurrent diuretic use, anti-coagulation or anti-platelet use. 8. Abnormal bleeding disorder. 9. On any "diet" recommended to treat MS (ex: Best Bet, Swank, McDougall, MS Recovery diet, Wahls', other Paleolithic, gluten-free, vegetarian, and/or vegan 10. Inability to maintain food log for for seven consecutive days during the run-in phase of the study. 11. Not comfortable using a computer. 12. Other failure to demonstrate compliance. |
Country | Name | City | State |
---|---|---|---|
United States | University of Iowa | Iowa City | Iowa |
Lead Sponsor | Collaborator |
---|---|
Amanda Irish |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Fatigue Severity Scale (FSS)-9 Score | Specific Aims: 1) Test the hypothesis that a modified Paleolithic diet reduces effects of fatigue in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS), compared to controls, in: (a) daily life as measured by the Fatigue Severity Scale (FSS) score. A 9-item sel-report questionnaire related to how fatigue interferes with certain activities and rates its severity, items are scored on a 7 point scale with 1 = strongly disagree and 7= strongly agree. The minimum score is 9 and maximum score is 63. Higher the score indicates greater fatigue severity. |
End of Study, measured at 3.5 months; Change from Baseline | |
Primary | Change in Paced Auditory Serial Addition Test (PASAT) Score | Specific Aims: 1) Test the hypothesis that a modified Paleolithic diet reduces effects of fatigue in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS), compared to controls, in: (b) cognitive fatigue as measured by the Paced Auditory Serial Addition Test (PASAT) score. The PASAT is a measure of cognitive function that assesses auditory information processing speed and flexibility, as well as calculation ability. The PASAT is presented using audio to ensure standardization in the rate of stimulus presentation. Single digits are presented every 3 seconds and the patient must add each new digit to the one immediately prior to it. The score for the PASAT (0-60) is the total number correct out of 60 possible answers. |
End of Study, measured at 3.5 months; Change from Baseline | |
Primary | Change in 6-minute Walk (6-MW) Distance | Specific Aims: 1) Test the hypothesis that a modified Paleolithic diet reduces effects of fatigue in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS), compared to controls, in: (c) physical fatigue as measured by the 6-minute (m) walk (6-MW). Timed 6-minute walk (6-MW): a submaximal measure of gait velocity and endurance over a distance (m) walked in 6 minutes. |
End of Study, 3.5 months; Change from Baseline | |
Primary | Change in (25-FW) 25-ft Walk Time | Specific Aims: 1) Test the hypothesis that a modified Paleolithic diet reduces effects of fatigue in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS), compared to controls, in: (d) physical fatigue as measured by the 25-ft walk (25-FW; (s). Timed 25-Foot Walk (T25-FW): a quantitative test of maximal walking velocity, mobility, dynamic balance and leg function. The subject is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly and as safely, as possible. The time is recorded from the first step across the line and ends when the patient crosses the same foot over the 25-foot mark. The task is immediately administered again by having the patient walk back the same distance. Patients may use assistive devices when doing this task. |
End of Study, measured at 3.5 months; Change from Baseline | |
Secondary | Quality of Life (MSQOL-54) | Test the hypothesis that a modified Paleolithic diet improves general well-being/health and quality of life of RRMS patients, compared to controls, as measured by: Multiple Sclerosis Quality of Life-54 (MSQOL-54) Mental and Physical Health scores. Multiple Sclerosis Quality of Life-54 (MSQOL-54): a multidimensional health-related quality of life survey that combines both generic and MS-specific items into a single instrument. Higher scores (0-100) indicate improved health. |
End of Study, measured at 3.5 months; Change from Baseline | |
Secondary | Quality of Life (Vitamin B-1 Blood Serum Measures) | Test the hypothesis that a modified Paleolithic diet improves general well-being/health and quality of life of RRMS patients, compared to controls, as measured by vitamin B-1 (thiamine) blood serum measures. | End of Study, measured at 3.5 months; Change from Baseline | |
Secondary | Quality of Life (Vitamin B-9 Blood Serum Measures) | Test the hypothesis that a modified Paleolithic diet improves general well-being/health and quality of life of RRMS patients, compared to controls, as measured by vitamin B-9 (folate) blood serum measures. | End of Study, measured at 3.5 months; Change from Baseline | |
Secondary | Quality of Life (Vitamins B-12 and K Blood Serum Measures) | Test the hypothesis that a modified Paleolithic diet improves general well-being/health and quality of life of RRMS patients, compared to controls, as measured by blood serum measures: vitamin B-12 (cobalamin) and vitamin K. | End of Study, measured at 3.5 months; Change from Baseline | |
Secondary | Quality of Life (Homocysteine Blood Serum Measures) | Test the hypothesis that a modified Paleolithic diet improves general well-being/health and quality of life of RRMS patients, compared to controls, as measured by homocysteine (HCY) blood serum measures. | End of Study, measured at 3.5 months; Change from Baseline | |
Secondary | Quality of Life (C-reactive Protein Blood Serum Measures) | Test the hypothesis that a modified Paleolithic diet improves general well-being/health and quality of life of RRMS patients, compared to controls, as measured by C-reactive protein (hs-CRP) blood serum measures. | End of Study, measured at 3.5 months; Change from Baseline | |
Secondary | Quality of Life (9-HPT) | Test the hypothesis that a modified Paleolithic diet improves general well-being/health and quality of life of RRMS patients, compared to controls, as measured by the 9-Hole Peg Test (9-HPT). 9-Hole Peg Test: a brief, standardized, quantitative test of upper extremity function. The patient is seated at a table with a small, shallow container holding nine pegs and a wood or plastic block containing nine empty holes (Rolyan 9-Hole Peg Test Kit - Model A8515). On a start command a stopwatch is started, the patient picks up the nine pegs one at a time as quickly as possible, puts them in the nine holes, and, once they are in the holes, removes them again as quickly as possible one at a time, replacing them into the shallow container. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The score for the 9-HPT is an average of the two trials for each hand. |
End of Study, measured at 3.5 months; Change from Baseline | |
Secondary | Quality of Life (VSAQ) | Test the hypothesis that a modified Paleolithic diet improves general well-being/health and quality of life of RRMS patients, compared to controls, as measured by the Veterans Specific Activity Questionnaire (VSAQ). Veterans Specific Activity Questionnaire (VSAQ): a self-reported survey instrument that serves as a strong predictor of both measured and predicted exercise capacity. Subjects identify a series of activities that they can complete on a typical day (scaled 1-11 for estimated metabolic equivalents (METs)), higher METs indicate increased exercise capacity. |
End of Study, measured at 3.5 months; Change from Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02861014 -
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
|
Phase 3 | |
Terminated |
NCT01435993 -
Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis
|
Phase 1 | |
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Completed |
NCT02410200 -
Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS
|
Phase 2 | |
Completed |
NCT03975413 -
Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis
|
||
Completed |
NCT05080270 -
Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis
|
Early Phase 1 | |
Completed |
NCT01116427 -
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT01108887 -
An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmartâ„¢.
|
N/A | |
Completed |
NCT01141751 -
An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy
|
N/A | |
Completed |
NCT00097331 -
Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT01909492 -
Measurement of Relaxin Peptide in Multiple Sclerosis (MS)
|
||
Completed |
NCT04121221 -
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
|
Phase 3 | |
Not yet recruiting |
NCT05290688 -
Cellular microRNA Signatures in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT04880577 -
Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04528121 -
Effect of CoDuSe Balance Training and Step Square Exercises on Risk of Fall in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT04002934 -
Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis
|
Phase 2 | |
Recruiting |
NCT05019248 -
Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
|
||
Completed |
NCT04580381 -
Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort
|
||
Completed |
NCT00071838 -
Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
|
Phase 2 |